(Q34357427)

1 August 2017

title

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer (English)

1 reference

1 August 2017

1 reference

V Heinemann

1

1 reference

1 August 2017

M Haas

series ordinal

2

1 reference

1 August 2017

S Boeck

series ordinal

3

1 reference

1 August 2017

publication date

12 July 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

24

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

2484-2492

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

1 August 2017

1 reference

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT239

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT239

1 reference

1 August 2017

1 reference